Baidu
map

PLoS ONE:靶向肺的药物递送载体成功减轻肺部炎症

2014-07-18 佚名 生物谷

对于经历多次输血,肺部手术的人,以及败血症,急性肺创伤患者来说,肺部炎症会引起浅呼吸以及肺部进一步的损伤。迄今为止,还没有药物能成功地预防或减轻肺部炎症引起的肺损伤。 现在,由David Eckmann医学博士领导的一个多学科研究小组发现,利用一个微小转运载体即纳米载体,可以成功递送地塞米松到达肺血管的内皮细胞,并且新的递送系统能成功地预防小鼠肺部炎症。相关研究发表在PLOS One杂志上。 在

对于经历多次输血,肺部手术的人,以及败血症,急性肺创伤患者来说,肺部炎症会引起浅呼吸以及肺部进一步的损伤。迄今为止,还没有药物能成功地预防或减轻肺部炎症引起的肺损伤。【pdf free】 

现在,由David Eckmann医学博士领导的一个多学科研究小组发现,利用一个微小转运载体即纳米载体,可以成功递送地塞米松到达肺血管的内皮细胞,并且新的递送系统能成功地预防小鼠肺部炎症。相关研究发表在PLOS One杂志上。

在过去的一年中,研究团队将计算机模拟实验和实验相结合,设计出靶向给药的纳米载体。该小组使用一种纳米凝胶(用于递送药物的纳米载体),该纳米凝胶由两个分子:右旋糖酐(糖)和溶菌酶(一种蛋白质)组成,另外,将一个特异性的靶向肺的分子附着于载体表面,并且将地塞米松加载到纳米凝胶中。此纳米载体会结合到肺血管衬里的内皮细胞中。 




由于纳米载体表面上的肺靶向分子特异性“偏爱”肺,所以纳米载体能特异性的到达肺部血管,该小组下一步计划尝试使用该纳米载体技术来治疗患者的肺部炎症。

原始出处:

Coll Ferrer MC1, Shuvaev VV2, Zern BJ2, Composto RJ3, Muzykantov VR2, Eckmann DM4.Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation.PLoS One. 2014 Jul 14;9(7):e102329. doi: 10.1371/journal.pone.0102329. eCollection 2014.【pdf free

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645416, encodeId=f75716454169c, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Mon Sep 08 18:19:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789609, encodeId=e50c1e896093d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue May 19 07:19:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940591, encodeId=7a5819405917f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sat Jul 26 21:19:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811359, encodeId=c0b81811359a3, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 13 15:19:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2014-09-08 mei539
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645416, encodeId=f75716454169c, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Mon Sep 08 18:19:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789609, encodeId=e50c1e896093d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue May 19 07:19:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940591, encodeId=7a5819405917f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sat Jul 26 21:19:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811359, encodeId=c0b81811359a3, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 13 15:19:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645416, encodeId=f75716454169c, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Mon Sep 08 18:19:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789609, encodeId=e50c1e896093d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue May 19 07:19:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940591, encodeId=7a5819405917f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sat Jul 26 21:19:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811359, encodeId=c0b81811359a3, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 13 15:19:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645416, encodeId=f75716454169c, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Mon Sep 08 18:19:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789609, encodeId=e50c1e896093d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue May 19 07:19:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940591, encodeId=7a5819405917f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sat Jul 26 21:19:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811359, encodeId=c0b81811359a3, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 13 15:19:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]

相关资讯

Chest:经过培训的肺科医生可自行对TBNA样本的适宜性进行快速现场评估

图1垂直轴和水平轴分别显示肺病学家与细胞病理学家对标本的分类。球体的大小代表两位医生之间对每个类别分类一致或不一致的例数。红色球表示假阳性,蓝色表示假阴性,绿色表示真阳性,黄色表示诊断未确定的样本。在肺及纵隔病变的针吸细胞学检查过程中,对细胞学标本的现场快速评价(ROSE)是一项有用的辅助技术。然而,由于时间和人手的限制,ROSE的应用并不普遍。在对肺门或纵隔淋巴结肿大/肿物进行经支气管针吸活检(

NEJM:新生儿高频率振荡通气远期疗效好

极低胎龄儿通常需要进行机械通气,高频振荡通气(HFOV)是一种可减少支气管-肺发育不良风险的治疗手段,通过施加恒定的气道压力改善肺容积与氧合。有报道早产儿常规机械通气会导致小气道功能下降,但研究并未发现初始给予HFOV支持的婴儿会出现小气道功能的明显下降。 尽管荟萃分析结果表明,HFOV可减少支气管-肺发育不良的风险,但目前关于接受HFOV婴幼儿肺功能的随访数据有限。为确定HFOV的长期疗效,研

A&R:甲氨蝶呤可增加RA患者肺部疾病的发生

甲氨蝶呤对很多疾病有治疗效果,尤其是类风湿关节炎。既往的研究提示甲氨蝶呤有可能会引起间质性肺疾病,并且增加呼吸系统感染的风险。为了明确甲氨蝶呤治疗RA患者罹患肺部疾病的危险度,来自爱尔兰国立高威大学医院的Richard Conway 等研究者对既往的相关研究结果进行了Meta分析,结果发表在2014年Arthritis & Rheumatism杂志上。 这项分析纳入的数据来自Pubmed

Chest:药物治疗肺动脉高压疗效和安全性比较

目前,用于肺动脉高压(PAH)治疗的药物主要有三类,即内皮素受体拮抗剂、磷酸二酯酶-5抑制剂和前列腺素。这些药都显示具有改善患者呼吸困难、6分钟步行距离(6MWD)和肺血液动力学的作用。然而很少有关于不同药物联合治疗的有效性和安全性比较,或药物治疗对死亡率影响的研究。 来自美国北卡罗莱纳州杜克大学医学院的Coeytaux教授等进行的一项系统评价和Mata分析显示,单药及药物联合治疗可使肺动脉高压

Expert Rev Respir Med:间质性肺疾病使用免疫抑制剂相关技巧

免疫抑制在间质性肺疾病(ILD)治疗中有重要作用,其对某些ILD,如特发性肺纤维化(IPF)无效,对另一些则效果较好。同时,其可能带来的风险也很大,如:感染,糖尿病,骨质疏松,肌病,骨髓抑制,肝炎,泌尿道损伤,药物性肺炎等。本文将阐述在ILD中是否应使用免疫抑制治疗,怎样使用,怎样监测,以及怎样减少可能的副作用等。 使用免疫抑制剂治疗ILD的证据 在ILD中,常用的免疫抑制是激素和细胞毒性药物

Ann Thorac Surg:高手术风险NSCLC接受肺段切除有助于淋巴结分期和边缘切除

早期肺癌和肺储备功能有限的患者可能不是肺叶切除术的合适人选。在这种情况下,一般进行亚肺叶切除(楔形或肺段切除)。许多医生认为肺段切除具有优越性,因为它可以改善切缘和淋巴结取样。但在这方面数据仍比较缺乏。针对这种情况,来自波士顿的贝斯以色列女执事医疗中心外科部的MichaelKent博士等人进行了一项研究,研究结果在线发表于2013年8月30日的《胸外科年鉴》(AnnThoracSurg)杂志上。作

Baidu
map
Baidu
map
Baidu
map